Hydrogen Water Shows Promise for Treating Fatty Liver Disease (NASH)
- Authors
- Akinobu Takaki, Daisuke Kawai, Kazuhide Yamamoto
- Journal
- International Journal of Molecular Sciences
- Year
- 2013
- DOI
- 10.3390/ijms141020704
- Study Type
- clinical
- Peer Reviewed
- Yes
- Country
- Japan
- Health Condition
- Non-alcoholic Steatohepatitis (NASH)
- Body System
- Hepatic
TL;DR
Scientists found that a special type of antioxidant called molecular hydrogen might be really good at treating a liver disease called NASH, which happens when fat builds up in your liver and causes damage—and it could even stop it from turning into liver cancer.
Key Finding
Molecular hydrogen may be a more effective antioxidant for treating NASH than conventional antioxidant drugs because it selectively reduces only cytotoxic reactive oxygen species rather than blocking all oxidative stress.
Summary
Non-alcoholic fatty liver disease (NASH) develops when multiple factors—including genetics, insulin resistance, and gut bacteria—cause fat and inflammation to build up in the liver. The study explains that oxidative stress (cellular damage from harmful molecules called reactive oxygen species) plays a key role in this progression. While regular antioxidant drugs have shown short-term benefits, they often fail long-term because they block all oxidative stress, not just the harmful kind. The authors propose that molecular hydrogen may work better because it selectively targets only the most damaging reactive oxygen species, potentially preventing progression to liver cancer.
Practical Takeaway
This is a review article proposing hydrogen as a potential treatment for NASH, not a clinical trial with human results. While the selective antioxidant mechanism of hydrogen is theoretically promising, long-term human studies are needed to determine whether hydrogen-rich water actually prevents liver disease progression. Anyone with fatty liver disease should consult their doctor rather than self-treating with hydrogen water.
Abstract
Multiple parallel hits, including genetic differences, insulin resistance and intestinal microbiota, account for the progression of non-alcoholic steatohepatitis (NASH). Multiple hits induce adipokine secretion, endoplasmic reticulum (ER) and oxidative stress at the cellular level that subsequently induce hepatic steatosis, inflammation and fibrosis, among which oxidative stress is considered a key contributor to progression from simple fatty liver to NASH. Although several clinical trials have shown that anti-oxidative therapy can effectively control hepatitis activities in the short term, the long-term effect remains obscure. Several trials of long-term anti-oxidant protocols aimed at treating cerebrovascular diseases or cancer development have failed to produce a benefit. This might be explained by the non-selective anti-oxidative properties of these drugs. Molecular hydrogen is an effective antioxidant that reduces only cytotoxic reactive oxygen species (ROS) and several diseases associated with oxidative stress are sensitive to hydrogen. The progress of NASH to hepatocellular carcinoma can be controlled using hydrogen-rich water. Thus, targeting mitochondrial oxidative stress might be a good candidate for NASH treatment. Long term clinical intervention is needed to control this complex lifestyle-related disease.